WPI Bioengineering Institute to Hold Annual Corporate Forum March 25
This year's forum explores the increasingly segmented development processes from discovery to commercial product for new therapeutics or medical devices. Kevin O'Sullivan, president of Massachusetts Biomedical Initiatives, delivers the keynote address.
Keynote by Kevin O’Sullivan, President, Massachusetts Biomedical Initiatives
Getting from discovery to commercial product for new therapeutics or medical devices is an increasingly segmented process, with universities and companies focused on core-competencies along the development chain. As a result, the roles of service providers, alliances and partnerships continue to grow in scope and complexity in the pharmaceutical, biotechnology and bioengineering industries. Speakers from a range of companies will discuss their respective roles in the development chain and how they interact with other companies and universities.
Wednesday, March 25, 2009, from 1 p.m. to 5 p.m.
WPI Campus Center Odeum (On Main Campus)
AVATAR: Judy Carmody, Ph.D., President
Charles River Labs: Cheri Walker, Ph.D., Senior Vice President
Crescent Innovations Inc.: Al Prescott, President
Intertech Engineering Associates Inc.: David Vogel, Ph.D., President
Blue Sky Biotech: Norman Garceau, Ph.D., President & Chief Scientific Officer
Kevin O'Sullivan, President, Massachusetts Biomedical Initiatives
The WPI Bioengineering Institute is an interdisciplinary research and development organization blending academic, industry, and government partnerships to develop and commercialize innovative, life sciences-based technologies. In BEI's seven multidisciplinary centers, scientists, engineers, and clinicians address important research challenges in several major areas of medical technology and healthcare, including bioprocessing, imaging, nanotechnology, remote diagnostics and treatment, sensing, and water quality.